Abstract
The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for the development of novel anticancer agents designed to selectively block the growth and proliferation of tumor cells. Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via structure-based drug design that have contributed to the number of compounds undergoing clinical development.
Keywords: Hsp90, heat shock protein, cancer, inhibitor, molecular chaperone, protein folding, geldanamycin, radicicol
Current Cancer Drug Targets
Title: Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades
Volume: 7 Issue: 4
Author(s): Stephanie C. Bishop, Joseph A. Burlison and Brian S. J. Blagg
Affiliation:
Keywords: Hsp90, heat shock protein, cancer, inhibitor, molecular chaperone, protein folding, geldanamycin, radicicol
Abstract: The 90 kDa heat shock proteins (Hsp90) are proving to be an excellent target for the development of novel anticancer agents designed to selectively block the growth and proliferation of tumor cells. Since Hsp90 is a molecular chaperone and is responsible for folding numerous oncogenic proteins, its inhibition represents a novel approach toward the simultaneous disruption of multiple signaling cascades. This review summarizes recent literature implicating Hsp90 as a key facilitator for the maturation of proteins represented in all six hallmarks of cancer: 1) growth signal self-sufficiency, 2) anti-growth signal insensitivity, 3) evasion of apoptosis, 4) unlimited replicative potential, 5) metastasis and tissue invasion, and 6) sustained angiogenesis. Also described are recent advances towards the development of novel Hsp90 inhibitors via structure-based drug design that have contributed to the number of compounds undergoing clinical development.
Export Options
About this article
Cite this article as:
Bishop C. Stephanie, Burlison A. Joseph and J. Blagg S. Brian, Hsp90: A Novel Target for the Disruption of Multiple Signaling Cascades, Current Cancer Drug Targets 2007; 7 (4) . https://dx.doi.org/10.2174/156800907780809778
DOI https://dx.doi.org/10.2174/156800907780809778 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Treatment of Elderly Patients Affected by Lung Cancer: Why to Treat, when to Treat and what we Know
Anti-Cancer Agents in Medicinal Chemistry Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy
Current Drug Targets CD26/Dipeptidyl Peptidase IV as a Novel Therapeutic Target for Cancer and Immune Disorders
Mini-Reviews in Medicinal Chemistry Pulmonary Hypertension: Current Therapy and Future Prospects
Cardiovascular & Hematological Agents in Medicinal Chemistry Histone Deacetylase Inhibitors: A Review on Class-I Specific Inhibition
Mini-Reviews in Medicinal Chemistry BUB1B Promotes Proliferation of Prostate Cancer via Transcriptional Regulation of MELK
Anti-Cancer Agents in Medicinal Chemistry Multiple Pharmacological Properties of a Novel Parthenin Analog P16 as Evident by its Cytostatic and Antiangiogenic Potential Against Pancreatic Adenocarcinoma PANC -1 Cells
Anti-Cancer Agents in Medicinal Chemistry COX-2 and Colorectal Cancer
Current Pharmaceutical Design Role of microRNA and Long Non-Coding RNA in Hepatocellular Carcinoma
Current Pharmaceutical Design Selective Estrogen Receptor Modulators and Aromatase Inhibitors for Breast Cancer Chemoprevention
Current Drug Targets Effect of an Angiotensin II Receptor Blocker and Two Angiotensin Converting Enzyme Inhibitors on Transforming Growth Factor-β (TGF-β) and α-Actomyosin (α SMA), Important Mediators of Radiation-Induced Pneumopathy and Lung Fibrosis
Current Pharmaceutical Design Tissue Biomarkers for Prostate Cancer Radiation Therapy
Current Molecular Medicine Environmentally Sensitive Paramagnetic and Diamagnetic Contrast Agents for Nuclear Magnetic Resonance Imaging and Spectroscopy
Current Topics in Medicinal Chemistry Novel Insights and Therapeutical Applications in the Field of Inhibitors of COX-2
Current Medicinal Chemistry Targeted Drug Delivery for Breast Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery Reprogrammed Metabolism of Cancer Cells as a Potential Therapeutic Target
Current Pharmaceutical Design Mango Polyphenols and Its Protective Effects on Diseases Associated to Oxidative Stress
Current Pharmaceutical Biotechnology Molecular Mechanisms of Resistance in Testicular Germ Cell Tumors - clinical Implications
Current Cancer Drug Targets Novel Drugs and the Response to Hypoxia: HIF Stabilizers and Prolyl Hydroxylase
Recent Patents on Cardiovascular Drug Discovery Simultaneous Separation, Quantitation, and Determination of the Dissociation Constant of Five Components of Ixeris sonchifolia by Microemulsion Electrokinetic Chromatography
Current Pharmaceutical Analysis